Myovant Sciences Ltd

From Verify.Wiki
Jump to: navigation, search
Myovant.png
http://myovant.com/
Myovant Sciences Ltd
Type Public
Industry Biopharmaceutical
Founded 2016
Headquarters Hamilton, Bermuda.
Key people Lynn Seely M.D. (CEO, President and Executive Director), Frank L. Karbe (Principal Financial and Accounting Officer), Marianne L. Romeo [1]
Number of employees 9

Myovant Sciences is focused on innovative treatments for women's health conditions and prostate cancer. The company's lead program is relugolix, a phase 3 drug candidate for multiple indications, including uterine fibroids, endometriosis and prostate cancer. Myovant was formed through a strategic partnership between Roivant Sciences and Takeda.[2] [3]
Osaka, Japan-based Takeda Pharmaceutical Company (TKPYY) and Hamilton, Bermuda-based Roivant Sciences came together and launched Myovant Sciences.Roivant Sciences spun out of Axovant Sciences (AXON) in May 2014. [4]
The company recently filed for an IPO of up to $172.5 million; applied to list common shares on NYSE under symbol "MYOV".

Products

Its lead product candidate is Relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The company also intends to develop RVT-602, an oligopeptide kisspeptin analog, for the treatment of female infertility as part of assisted reproduction.

Controversies

None Reported

Top 5 Recent Tweets

DateAuthorComment
October 21, 2020semodough$MYOV Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and… https://t.co/SoTSzdTCLk


Top 5 Recent News Headlines

  • Myovant Sciences Ltd. Announces Board Appointments - Myovant Sciences Ltd. has announced additions to its Board of Directors. The Board of Directors Comprised of Biopharmaceutical and Healthcare Industry Veterans. [5]
  • Myovant Sciences files for IPO - Files for IPO of up to $172.5 million; applied to list common shares on NYSE under symbol "MYOV" [6]
  • Former Medivation (MDVN) CMO Takes Helm at Roivant Sciences-Takeda (TKPYY)'s Newly Launched Company Myovant Sciences - Osaka, Japan-based Takeda Pharmaceutical Company (TKPYY) and Hamilton, Bermuda-based Roivant Sciences, announced that they had together launched Myovant Sciences. [7]
  • Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative Therapeutics for Women's Health and Prostate Cancer - - Myovant to conduct global phase 3 programs of relugolix, a potential best-in-class GnRH antagonist for the treatment of uterine fibroids, endometriosis and prostate cancer. [8]
  • Myovant Sciences Ltd. Auditor Raises 'Going Concern' Doubt - In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. [9]

References

  1. http://myovant.com/management
  2. http://www.forbes.com/sites/nathanvardi/2016/07/13/billionaire-andreas-halvorsens-hedge-fund-backs-private-biotech-roivant-sciences/#2f3e6a166443
  3. http://www.prnewswire.com/news-releases/roivant-sciences-and-takeda-launch-myovant-sciences-to-develop-innovative-therapeutics-for-womens-health-and-prostate-cancer-300279891.html
  4. http://www.biospace.com/News/former-medivation-cmo-takes-helm-at-roivant/422106
  5. http://www.bloomberg.com/Research/stocks/private/snapshot.asp?privcapId=403430039
  6. http://www.reuters.com/article/idUSFWN1C60QX
  7. http://www.biospace.com/News/former-medivation-cmo-takes-helm-at-roivant/422106
  8. http://www.prnewswire.com/news-releases/roivant-sciences-and-takeda-launch-myovant-sciences-to-develop-innovative-therapeutics-for-womens-health-and-prostate-cancer-300279891.html
  9. http://www.bloomberg.com/Research/stocks/private/snapshot.asp?privcapId=403430039

Verification history